ABSI Stock Overview
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.76|
|52 Week High||US$31.53|
|52 Week Low||US$6.12|
|1 Month Change||-23.27%|
|3 Month Change||-41.97%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-68.69%|
Recent News & Updates
Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen its market cap fall from >$2bn, to $665m at the time of writing. This isn't unusual for a drug discoverer/developer - Abcellera, also based in Vancouver, has seen its stock fall >80% while even Ginkgo Bioworks stock is -30% since IPO. Absci has recently announced a partnership with Merck for up to three candidates which could be worth up to $640m, if all milestones are met. That's not necessarily likely but it does serve as validation of the young company's technology and approach. Merck is revamping its R&D and Absci could make itself an indispensable part of that. The deal will not do much for Merck in the short term, but it may help push Absci's valuation higher - shares were 44%-plus on the news. Investing with a five-year investment horizon may offer a good ROI.
IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today. CEO Sean McClain discusses the emotion around going public, acquisitions in the time of Covid and being a technology driven company. Providing tech solutions for pharma partners and what metric is key to watch over the next year.
|ABSI||US Life Sciences||US Market|
Return vs Industry: Insufficient data to determine how ABSI performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how ABSI performed against the US Market.
|ABSI Average Weekly Movement||14.2%|
|Life Sciences Industry Average Movement||9.1%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ABSI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ABSI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Fundamentals Summary
|ABSI fundamental statistics|
Is ABSI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABSI income statement (TTM)|
|Cost of Revenue||US$33.42m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.91|
|Net Profit Margin||-1,383.25%|
How did ABSI perform over the long term?See historical performance and comparison
Is Absci undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABSI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABSI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABSI is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: ABSI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABSI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABSI is good value based on its PB Ratio (1.6x) compared to the US Life Sciences industry average (3.2x).
How is Absci forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABSI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABSI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABSI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABSI's revenue (51.6% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: ABSI's revenue (51.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABSI is forecast to be unprofitable in 3 years.
How has Absci performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ABSI is currently unprofitable.
Growing Profit Margin: ABSI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ABSI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ABSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABSI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).
Return on Equity
High ROE: ABSI has a negative Return on Equity (-20.81%), as it is currently unprofitable.
How is Absci's financial position?
Financial Position Analysis
Short Term Liabilities: ABSI's short term assets ($300.7M) exceed its short term liabilities ($30.2M).
Long Term Liabilities: ABSI's short term assets ($300.7M) exceed its long term liabilities ($30.9M).
Debt to Equity History and Analysis
Debt Level: ABSI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABSI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABSI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ABSI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 103.1% each year
What is Absci current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABSI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABSI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sean McClain (31 yo)
Mr. Sean Mcclain is the Founder of Absci Corporation (formerly known as AbSci, LLC) and serves as its Chief Executive Officer since August 2011 and Director since its formation in October 2020. Mr. Mcclain...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD1.18M) is below average for companies of similar size in the US market ($USD2.38M).
Compensation vs Earnings: Insufficient data to compare Sean's compensation with company performance.
Experienced Management: ABSI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: ABSI's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABSI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: ABSI only recently listed within the past 12 months.
Absci Corporation's employee growth, exchange listings and data sources
- Name: Absci Corporation
- Ticker: ABSI
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$625.918m
- Shares outstanding: 92.59m
- Website: https://www.absci.com
Number of Employees
- Absci Corporation
- 18105 SE Mill Plain Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 23:54|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.